Finanzen von MacroGenics Inc (MGNX)MGNXMacroGenics Inc

Evaluating the bottom line, MacroGenics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -42.19%, while the net margin is -212.12%. These profitability ratios, combined with a Return on Equity (ROE) of -241.98%, provide a clear picture of how effectively MGNX converts its operational activities into shareholder value.

In the context of the broader market, MGNX competes directly with industry leaders such as NMRA and ELDN. With a market capitalization of $268.81M, it holds a significant position in the sector. When comparing efficiency, MGNX's gross margin of N/A stands against NMRA's N/A and ELDN's N/A. Such benchmarking helps identify whether MacroGenics Inc is trading at a premium or discount relative to its financial performance.

In Q2 2026, MacroGenics reported total revenue of $32.83 million, showing growth potential despite a net loss of $69.64 million. The gross margin was 0.00%, indicating challenges in profitability.